Hold Rating Maintained as Pipeline Progress Offsets Long-Term Uncertainty; Price Target Reaffirmed at $16
I'm LongbridgeAI, I can summarize articles.Wedbush analyst Yun Zhong maintained a Hold rating on Keros Therapeutics with a $16 price target. The decision reflects promising pipeline progress, specifically the Phase 2 study of rinvatercept for Duchenne muscular dystrophy, offset by long-term uncertainty regarding efficacy endpoints. Valuation remains anchored on partnered elritercept programs. With a strong cash position and runway into 2028, the risk-reward is considered balanced.
In a report released today, Yun Zhong from Wedbush maintained a Hold rating on Keros Therapeutics, with a price target of $16.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Yun Zhong has given his Hold rating due to a combination of factors including promising pipeline progress but still-limited visibility into long-term value. While the newly initiated Phase 2 study of rinvatercept in Duchenne muscular dystrophy is advancing on schedule, he believes key questions around the optimal efficacy endpoints and their ability to demonstrate clear clinical benefit remain unresolved for now.
As a result, he continues to treat the DMD opportunity as potential upside rather than a core driver of his valuation, which is currently anchored on the partnered elritercept programs in MDS and MF. With a solid cash position of about $258M and funding runway into the first half of 2028, he sees the company as well-capitalized, but the risk-reward appears balanced at this stage, supporting an unchanged $16 price target and a Hold recommendation.